News
-
-
COMMUNIQUÉ DE PRESSE
AB Science fait le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA
AB Science annonce un avis négatif sur la demande de mise sur le marché du masitinib dans la SLA et prévoit un réexamen du dossier. Détails sur les raisons et les prochaines étapes -
COMMUNIQUÉ DE PRESSE
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
AB Science receives negative opinion from CHMP on masitinib's conditional marketing authorization for ALS treatment but plans re-examination due to urgent patient need and safety considerations -
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: SPORTTOTAL AG successfully completes capital increase
SPORTTOTAL AG successfully completes capital increase, raising EUR 1,384,132.00. New shares issued to shareholders and strategic investors for business expansion and working capital. Trading on Frankfurt Stock Exchange expected in calendar week 28 of 2024 -
-
-
COMMUNIQUÉ DE PRESSE
Redx Reports Encouraging Zamaporvint (RXC004) Phase 2 Combination Data in MSS mCRC at ESMO GI Congress Supporting Genetic Selection Hypothesis in Hard-to-Treat GI Cancers
Redx Pharma presents positive Phase 2 data on Zamaporvint (RXC004) at ESMO GI Congress, supporting genetic selection hypothesis in hard-to-treat GI cancers. Potential new treatment option for MSS mCRC patients -
-
-
